Newron Pharmaceuticals SpA (XSWX:NWRN) Scaled Net Operating Assets: -0.03 (As of Dec. 2025)


XSWX:NWRN Newron Pharmaceuticals SpA XSWX:NWRN
62 GF Score
Price CHF13.04
GF Value CHF12.95
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Newron Pharmaceuticals SpA Scaled Net Operating Assets?

Newron Pharmaceuticals SpA XSWX:NWRN +3.16% 62 Scaled Net Operating Assets is -0.03 as of Dec. 2025. GuruFocus rates XSWX:NWRN with a GF Score™ of 62/100 and a GF Value™ of CHF12.95 (Fairly Valued). The stock has 5 warning signs investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Newron Pharmaceuticals SpA's operating assets for the quarter that ended in Dec. 2025 was CHF10.43 Mil. Newron Pharmaceuticals SpA's operating liabilities for the quarter that ended in Dec. 2025 was CHF12.16 Mil. Newron Pharmaceuticals SpA's Total Assets for the quarter that ended in Jun. 2025 was CHF57.58 Mil. Therefore, Newron Pharmaceuticals SpA's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2025 was -0.03.

Newron Pharmaceuticals SpA Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Newron Pharmaceuticals SpA's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Newron Pharmaceuticals SpA Scaled Net Operating Assets Chart

Newron Pharmaceuticals SpA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.22 0.17 0.15 1.61 -0.03

Newron Pharmaceuticals SpA Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.18 0.23 1.64 0.17 -0.03

XSWX:NWRN vs VRTX, REGN, ALNY: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, Newron Pharmaceuticals SpA's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Newron Pharmaceuticals SpA Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Newron Pharmaceuticals SpA's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Newron Pharmaceuticals SpA's Scaled Net Operating Assets falls into.


XSWX:NWRN
62GF Score
Newron Pharmaceuticals SpA XSWX:NWRN
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Newron Pharmaceuticals SpA Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Newron Pharmaceuticals SpA's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2025 )
=(Operating Assets (A: Dec. 2025 )-Operating Liabilities (A: Dec. 2025 ))/Total Assets (A: Dec. 2024 )
=(10.432-12.156)/59.665
=-0.03

where

Operating Assets(A: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=37.377 - 26.945
=10.432

Operating Liabilities(A: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=47.767 - 0.544 - 35.067
=12.156

Newron Pharmaceuticals SpA's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Dec. 2025 )
=(Operating Assets (Q: Dec. 2025 )-Operating Liabilities (Q: Dec. 2025 ))/Total Assets (Q: Jun. 2025 )
=(10.432-12.156)/57.584
=-0.03

where

Operating Assets(Q: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=37.377 - 26.945
=10.432

Operating Liabilities(Q: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=47.767 - 0.544 - 35.067
=12.156

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of -0.03 mean?
Newron Pharmaceuticals SpA (XSWX:NWRN) has a Scaled Net Operating Assets of -0.03 as of Dec. 2025. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Newron Pharmaceuticals SpA and its competitors.
Is Newron Pharmaceuticals SpA's Scaled Net Operating Assets too high?
Newron Pharmaceuticals SpA's current Scaled Net Operating Assets is -0.03. Overall, Newron Pharmaceuticals SpA has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Newron Pharmaceuticals SpA's Scaled Net Operating Assets compare to VRTX and REGN?
Newron Pharmaceuticals SpA's Scaled Net Operating Assets of -0.03 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Newron Pharmaceuticals SpA and its competitors. Newron Pharmaceuticals SpA's current Scaled Net Operating Assets is -0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Newron Pharmaceuticals SpA stock overvalued right now?
Based on GuruFocus' analysis, Newron Pharmaceuticals SpA (XSWX:NWRN) is currently considered Fairly Valued. The stock's GF Value™ is CHF12.95, compared to a current price of CHF13.04 — trading 0.7% above its estimated fair value. The current Scaled Net Operating Assets is -0.03. Newron Pharmaceuticals SpA's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Newron Pharmaceuticals SpA (XSWX:NWRN), the current Scaled Net Operating Assets is -0.03 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Newron Pharmaceuticals SpA (XSWX:NWRN) Overvalued in 2026?

Based on GuruFocus' analysis, Newron Pharmaceuticals SpA stock appears to be overvalued. The current stock price of CHF13.04 is trading 0.7% above its estimated GF Value™ of CHF12.95. GuruFocus considers Newron Pharmaceuticals SpA to be Fairly Valued.

Key valuation signals for XSWX:NWRN:

  • Scaled Net Operating Assets: -0.03
  • GF Value™: CHF12.95 vs. price of CHF13.04 (0.7% above fair value)
  • GF Score™: 62/100 with 5 warning signs

No single metric tells the full story. See the XSWX:NWRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Newron Pharmaceuticals SpA Business Description

Other Exchanges NWRNz:UK0QOI:UKNP5:Germany
Address Via Antonio Meucci 3, Bresso, Milan, ITA, 20091
Newron Pharmaceuticals SpA is a Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson's disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Geographically the research and development activities are performed in Italy and the United States.
62GF Score

Get the complete analysis for XSWX:NWRN

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF13.04
Price
CHF12.95
GF Value